Skip to main content
TipRanks
Go Ultimate75% OFF

Pharma Mar SA (0RC6) Share Price & Analysis

1 Followers

0RC6 Stock Chart & Stats

€64.30-€2.35(-3.53%)
At close: 4:30 PM GMT
€70€80Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
EUR 64.25 - EUR 66.20
52-Week Range
EUR 62.40 - EUR 105.40
Previous Close
EUR 66.65
Volume
N/A
Average Volume (3M)
1,107
Market Cap
EUR 1.14B
Enterprise Value
EUR 1.16B
Total Cash (Recent Filing)
EUR 176.29M
Total Debt (Recent Filing)
EUR 70.07M
Price to Earnings (P/E)
16.2
Beta
0.45
Next Earnings
Mar 01, 2027 (Est.)
Dividend Yield
1.54%

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Positive revenue growth indicates stronger commercial traction and expanding demand for the company’s oncology portfolio. If sustained, this growth can support operating leverage, increase resources available for research and development, and strengthen Pharma Mar’s position with commercial partners over the next several quarters.

Recent Profitability

Strong current profitability provides an important foundation for a research-driven biopharmaceutical business, helping fund pipeline development and commercial activities internally. Healthy margins also offer greater resilience if product sales or collaboration income fluctuate during the next two to six months.

Manageable Leverage

Moderate debt relative to equity reduces pressure on operating cash flow and preserves flexibility for investment in oncology development and commercialization. This balance-sheet position gives Pharma Mar more capacity to manage business volatility than a highly leveraged capital structure would allow.

Bears Say

Cash-Flow Volatility

Uneven cash generation makes the company’s financial progress less dependable than its recent earnings suggest. Declining free cash flow and prior periods of negative operating cash flow can constrain internally funded research, commercialization, and partnering initiatives if volatility persists.

Balance-Sheet Cushion

The recent combination of higher debt and slightly lower equity reduces the balance-sheet cushion available if earnings weaken. Although leverage remains manageable, this trend could limit financial flexibility and increase reliance on future operating performance to support investment and obligations.

Earnings Volatility

Profitability has not been consistently durable across the reported periods, with near-break-even earnings and negative operating profitability in 2023. Such volatility indicates that strong TTM results may not fully represent normalized performance, complicating planning and long-term resource allocation.

Pharma Mar SA News

0RC6 FAQ

What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest share price was €62.40 and its highest was €105.40 in the past 12 months.
What is Pharma Mar SA’s market cap?
Pharma Mar SA’s market cap is €1.14B.
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s next earnings report is estimated for Mar 01, 2027 (not yet confirmed), which is in 103 days.
How were Pharma Mar SA’s earnings last quarter?
Pharma Mar SA released its earnings results on Oct 29, 2026. The company reported €0.46 earnings per share for the quarter, beating the consensus estimate of €0.127 by €0.333.
Is Pharma Mar SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA pays an annual dividend of €1 which represents an annual dividend yield of 1.54%. See more information on Pharma Mar SA dividends here
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is 0.40.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,000,000 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Pharma Mar SA reported an EPS of €0.46 in its last earnings report, beating expectations of €0.127. Following the earnings report the stock price went down -0.504%.
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in GB:0RC6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology